TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01260649
Drug: Muscle Relaxant
Normalized name: MUSCLE RELAXANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participant will receive routine course of muscle relaxant with ECT as per standard of care
Study: NCT01260649
Drug: Anesthetic Agents
Normalized name: General anesthetic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participant will receive routine course of anesthetic agents with ECT as per standard of care
Study: NCT02267239
Drug: essential oils, immersion
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single, 30-second immersion in 1 mL of essential oils in a hydroalcoholic solution (Listerine Mentol, Listerine®, Johnson \& Johnson, Madrid, Spain) (I-EO).
Study: NCT02267239
Drug: essential oils, mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single, 30-second mouthwash with 20 mL of essential oils in a hydroalcoholic solution (Listerine Mentol, Listerine®, Johnson \& Johnson, Madrid, Spain) (M-EO).
Study: NCT01433328
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00403390
Drug: Brand Name Levothyroxine (Synthroid)
Normalized name: levothyroxine Oral Tablet [Synthroid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized crossover study using 8 weeks of brand name levothyroxine (Synthroid, manufactured by Abbott), then 8 weeks of the generic formulation of levothyroxine (manufactured by Sandoz). The dose of medication does not change throughout the duration of the study.
Study: NCT00403390
Drug: Generic formulation of Levothyroxine
Normalized name: combinations of levothyroxine and liothyronine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized crossover study using 8 weeks of the generic formulation of levothyroxine (manufactured by Abbott, then 8 weeks of brand name levothyroxine (Synthroid, manufactured by Abbott). The dose of medication does not change throughout the duration of the study.
Study: NCT01497899
Drug: E/C/F/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150/150/200/300 mg FDC tablet administered orally once daily
Study: NCT01497899
Drug: E/C/F/TAF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally once daily
Study: NCT01497899
Drug: E/C/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150/150/200/10 mg FDC tablet administered orally once daily
Study: NCT01497899
Drug: E/C/F/TDF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally once daily
Study: NCT03000413
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01396486
Drug: Inositol
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Children with bipolar spectrum disorders ages 6-12 will receive treatment with inositol, omega-3 fatty acids, or both weekly for 12 weeks. Subjects weighing 25kg or more may be randomized to receive 2000mg (4 500mg capsules) of inositol (80mg/kg for a 25kg child). Children weighing less than 25kg will be dosed at 80mg/kg rounded down to the nearest thousand mg dose. Dosage will remain constant throughout the study.
Study: NCT01768039
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02642601
Drug: Indomethacin(KAHIRA PHARMA&CHEM,IND,CO.CAIRO-EGYPT)
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one dose of indomethacin 100 mg rectal suppository 1- 2 hours before embryo transfer
Study: NCT01694966
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic Methylene Blue MMX® tablet.
Study: NCT04384991
Drug: Restasis eye drop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine 0.05%
Study: NCT00086489
Drug: CP-675,206
Approvals — FDA: no, EMA: no, PMDA: no
Description: pts treated at 10 mg/kg dose level on a monthly regimen
Study: NCT00086489
Drug: CP-675,206
Approvals — FDA: no, EMA: no, PMDA: no
Description: pts treated at 15 mg/kg dose level on a quarterly regimen
Study: NCT01959594
Drug: 3 mg PF-06412562
Normalized name: fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral dosing of 3 mg PF-06412562 tablets three times a day for 14 days
Study: NCT01959594
Drug: 10 mg PF-06412562
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral dosing of 10 mg PF-06412562 tablets three times a day for 14 days
Study: NCT04437329
Drug: Docetaxel, nedaplatin, fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Nedaplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.
Study: NCT04437329
Drug: Docetaxel, cisplatin, fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Cisplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.
Study: NCT03404817
Drug: Original formulation EMB-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose (720 mg metyrapone/24 mg oxazepam)
Study: NCT03404817
Drug: New formulation EMB-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose (720 mg metyrapone/24 mg oxazepam)
Study: NCT03523819
Drug: CS1002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose levels will be escalated following a modified 3+3 dose escalation scheme
Study: NCT02954536
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03381144
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive GDC-0334-matching placebo.
Study: NCT04106297
Drug: GLPG3970 oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG3970 for oral administration
Study: NCT04106297
Drug: Placebo oral solution
Normalized name: Placebo Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for oral administration
Study: NCT04106297
Drug: GLPG3970 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG3970 for oral administration
Study: NCT03025282
Drug: CD10367 3% Solution - Non-desquamated zone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily application for 3 weeks
Study: NCT03025282
Drug: CD10367 1% Solution - Non-desquamated zone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily application for 3 weeks
Study: NCT03025282
Drug: CD10367 solution placebo - Non-desquamated zone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily application for 3 weeks
Study: NCT03025282
Drug: CD10367 3% Solution - Desquamated zone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily application for 3 weeks
Study: NCT03025282
Drug: CD10367 solution placebo - Desquamated zone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily application for 3 weeks
Study: NCT02194192
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 10 ml
Study: NCT01869907
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg once daily by mouth during 14 days
Study: NCT01869907
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily by mouth during 14 days
Study: NCT00193336
Drug: ZD1839
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03237481
Drug: HTX-011
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTX 011 (bupivacaine/meloxicam), 300 mg/9 mg by instillation
Study: NCT03237481
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo by instillation
Study: NCT01584232
Drug: LY2189265
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04052594
Drug: LY3475766 - IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT04052594
Drug: Placebo - IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT01584232
Drug: Sulfonylureas (SU)
Normalized name: Sus scrofa skin
DrugBank: Sus scrofa skin (DB10606)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00820014
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control (vehicle) eye drops applied 4-times a day for 4 days before ocular surgery
Study: NCT00788684
Drug: ABT-263
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-263: oral solution or tablets, once daily dosing until disease progression
Study: NCT03541850
Drug: Antiandrogen Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive luteinizing hormone-releasing hormone agonist or gonadotropin-releasing hormone antagonist, and oral anti-androgen
Study: NCT00715039
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo p.o. t.i.d. for 28 days; placebo matching lorazepam and paroxetine
Study: NCT02854072
Drug: GV1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: At week 1, GV1001 will be administered intradermally on day 1, day 3 and day 5. This will be followed by a once weekly schedule for weeks 2, 3, 4 and 6. After that, GV1001 will be administered once monthly until withdrawal from trial treatment due to patient choice, intolerable toxicity or disease progression. GM-CSF will be used as an adjuvant, given 10-15 minutes prior to each administration of GV1001.
Study: NCT02854072
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 830 mg/m\^2 will be orally given in the morning and evening (total dose of 1660 mg/m\^2) for 21 days followed by 7 days' rest.
Study: NCT03442244
Drug: LEO 90100 foam
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each subject has each of the 2 treatments applied at the same time on 2 different sites on the back
Study: NCT02570984
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo comparator arm, injection similar to active
Study: NCT00335699
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03254589
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: See arm descriptions
Study: NCT03028766
Drug: AZD1775
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1775 is a potent, selective small molecule inhibitor of WEE1
Study: NCT00115570
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection twice daily
Study: NCT02182622
Drug: LDE225
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00271635
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 4 capsules b.i.d. during 1 year
Study: NCT00271635
Drug: ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid 1000 mg (4 capsules of 250 mg) b.i.d. during 1 year
Study: NCT02830724
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For Phase I, Days -7 and -6:~Dose Level 1: 15 mg/kg/day x 2 days IV Dose Level 2: 15 mg/kg/day x 2 days IV Dose Level 3: 15 mg/kg/day x 2 days IV Dose Level 4: 15 mg/kg/day x 2 days IV Dose Level 5: 30 mg/kg/day x 2 days IV Dose Level 6: 60 mg/kg/day x 2 days IV~For Phase II, Days -7 and -6:~60 mg/kg/day x 2 days IV
Study: NCT04356222
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal chemotherapy specified dose on specified days
Study: NCT01216176
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02918370
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive ingredient matching the active comparators in appearance.
Study: NCT01187017
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg
Study: NCT00758732
Drug: Liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal doxorubicin at the dose of 20 mg/m2 over a 90 min intravenous infusion every 2 weeks in 28 days cycle for a maximum of 6 consecutive cycles.
Study: NCT02931188
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
Study: NCT02931188
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
Study: NCT00683436
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01596296
Drug: Dinoprostone 10mg
Normalized name: DINOPROSTONE 10MG INSERT,VAG
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dinoprostone vaginal insertion
Study: NCT01225874
Drug: SC-PEG E. coli L-asparaginase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IM
Study: NCT00677469
Drug: Placebo powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gram BID
Study: NCT01225874
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT
Study: NCT03668340
Drug: AZD1775
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1775 blocks the activity of Wee1, a protein that helps to regulate how cells divide and grow. Certain cancer cells may be more vulnerable to having this process blocked
Study: NCT04492033
Drug: CTX-009 (ABL001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTX-009 (ABL001) will be administered biweekly.
Study: NCT04781335
Drug: Standard of Care post operative eye drops (steroid, antibiotic, NSAID)
Normalized name: Sx1 Medicated Post-Operative System KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a contra-lateral randomized study, meaning that in clinic after a patient is identified as a candidate we will flip a coin for selection of the eye that is going to receive the Dexycu™ implant (the implant will be placed intracapsularly at the optic haptic junction of the IOL). The patients will receive the SAME topical regimen (Eye with Dexycu™: no steroid, Eye without Dexycu™: steroid will be used). The Dexycu™, topical NSAID, and antibiotic regimen will be provided to all patients in the study, at no cost, in order to avoid difficulties with compliance, insurance, and follow up.
Study: NCT02098343
Drug: APR-246
Normalized name: PrameGel Reformulated Apr 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion.
Study: NCT02098343
Drug: Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion.
Study: NCT04389775
Drug: Cohort A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in each cohort (A1 to A6) will be randomised to receive a SC dose of XW003 on Day 1 after overnight fasting by body weight range:~1. Proposed XW003 Dose Levels (50 kg-75 kg): 0.03mg, 0.1mg, 0.2mg, 0.4mg, 0.8mg and 0.6mg respectively for Cohorts A1 to A6.~2. Proposed XW003 Dose Levels (76 kg-90 kg): 0.03mg, 0.1mg, 0.25mg, 0.5mg, 1.0 mg and 0.6mg.~These doses are subject to change following SRC review of each cohort - XW003 dose level will not exceed 2.0 mg.
Study: NCT00245635
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets varying between 10mg and 80mg on a fixed/flexible dosing schedule based on the subjects' weight and side effects score.
Study: NCT04389775
Drug: Placebo A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in each cohort (A1 to A6) will be randomised to receive a SC dose of volume-matching placebo on Day 1 after overnight fasting by body weight range:~1. Proposed Placebo Dose Levels (50 kg-75 kg): 0.03mg, 0.1mg, 0.2mg, 0.4mg, 0.8mg, and 0.6mg respectively for Cohorts A1 to A6.~2. Proposed Placebo Dose Levels (76 kg-90 kg): 0.03mg, 0.1mg, 0.25mg, 0.5mg, 1.0 mg and 0.6mg.~These doses are subject to change following SRC review of each cohort - dose level will not exceed 2.0 mg.
Study: NCT04389775
Drug: Cohort B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in cohorts B1 to B3 (n=10 per cohort) will receive multiple SC doses of XW003 (n=8) once weekly for 6 weeks following an overnight fast of at least 10 hours.~1. Subject to change following SRC review of each cohort.~2. Following 4 weeks of once weekly dosing, the SRC will review the safety data (and PK data for Cohort B1 only) to determine the treatment for the following cohort and whether dosing can commence in parallel.~3. At least 3 days prior to Cohort B3 Week 3 (i.e., 3 days prior to the third dose in Cohort B3), the SRC will review the safety and PK data for Cohorts B1 and B2 to determine whether Cohort 3 dosing for Weeks 3 to 6 may commence.
Study: NCT04389775
Drug: Placebo B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in cohorts B1 to B3 (n=10 per cohort) will receive multiple SC doses of matching placebo (n=2) once weekly for 6 weeks following an overnight fast of at least 10 hours.~1. Subject to change following SRC review of each cohort.~2. Following 4 weeks of once weekly dosing, the SRC will review the safety data (and PK data for Cohort B1 only) to determine the treatment for the following cohort and whether dosing can commence in parallel.~3. At least 3 days prior to Cohort B3 Week 3 (i.e., 3 days prior to the third dose in Cohort B3), the SRC will review the safety and PK data for Cohorts B1 and B2 to determine whether Cohort 3 dosing for Weeks 3 to 6 may commence.
Study: NCT00245635
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets will be given 1x/day for the duration of the study at a fixed/flexible dosing schedule similar to that for the drug fluoxetine based off of subjects' weight and side effects score.
Study: NCT01590810
Drug: MK-8150 10 mg
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 10-mg dose of MK-8150
Study: NCT01590810
Drug: MK-8150 40 mg
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 40-mg dose of MK-8150 without food (fasted) and with food (fed)
Study: NCT01590810
Drug: MK-8150 90 mg
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 90-mg dose of MK-8150
Study: NCT01590810
Drug: MK-8150 5.0 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 5.0-mg dose of MK-8150
Study: NCT01590810
Drug: MK-8150 20 mg
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 20-mg dose of MK-8150
Study: NCT01590810
Drug: MK-8150 60 mg
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 60-mg dose of MK-8150
Study: NCT01590810
Drug: MK-8150 120 mg
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 120-mg dose of MK-8150
Study: NCT01590810
Drug: MK-8150 320 mg
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 320-mg dose of MK-8150
Study: NCT01590810
Drug: MK-8150 600 mg
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 600-mg dose of MK-8150
Study: NCT01590810
Drug: MK-8150 900 mg
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 900-mg dose of MK-8150
Study: NCT01590810
Drug: MK-8150 1200 mg
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 1200-mg dose of MK-8150
Study: NCT01590810
Drug: MK-8150 50 mg
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 50-mg dose of MK-8150
Study: NCT01590810
Drug: MK-8150 100 mg
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 100-mg dose of MK-8150
Study: NCT01590810
Drug: MK-8150 200 mg
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 200-mg dose of MK-8150
Study: NCT01590810
Drug: MK-8150 400 mg
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 400-mg dose of MK-8150
Study: NCT01590810
Drug: MK-8150 500 mg
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 500-mg dose of MK-8150
Study: NCT02669810
Drug: PROTHERACYTES
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProtheraCytes endocardiac injections performed with the HELIX and Morph catheters
Study: NCT02669810
Drug: Standard Treatment for CHF post AMI
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01721135
Drug: GSK2190915 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film coated oral tablet
Study: NCT01721135
Drug: GSK2190915 200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film coated oral tablet
Study: NCT01721135
Drug: GSK2190915 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film coated oral tablet
Study: NCT01293903
Drug: Qiliqiangxin capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qiliqiangxin capsule is administrated based on the standard heart failure treatment in China. Dosage: 1.2g/times. Frequency: 3 times/day. Duration: The whole study period.
Study: NCT01293903
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, similar in color and taste to Qiliqiangxin capsule, is administrated based on the standard heart failure treatment in China. Dosage: 1.2g/times. Frequency: 3 times/day. Duration: The whole study period.
Study: NCT02749396
Drug: Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
Study: NCT02749396
Drug: Extavia (interferon beta-1b), Novartis Pharma AG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
Study: NCT02749396
Drug: Rebif (interferon beta-1a), Merck Serono Europe Ltd
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
Study: NCT02749396
Drug: Plegridy (peginterferon beta-1a), Biogen Idec Ltd
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
Study: NCT02749396
Drug: Avonex (interferon beta-1a), Biogen Idec Ltd
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
Study: NCT02739230
Drug: On-Q pain intra-articular catheter
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01277016
Drug: BMDex
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMDex:~cycles 1 and 2 = MDex with bortezomib (B) at 1.3 mg/m2 i.v. on days 1, 4, 8 and 11 of a 28 day cycle, cycles 3 - 8 = MDex with bortezomib at 1.3 mg/m2 i.v. on days 1, 8, 15 and 22 of a 35 day cycle.
Study: NCT00174876
Drug: Drug Abilify
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00440232
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert tab identical in appearance to Frovatriptan